315 results match your criteria Neurodegenerative Disease Management [Journal]


Personality and the risk factors for developing behavioral and psychological symptoms of dementia: a narrative review.

Neurodegener Dis Manag 2019 Apr 18. Epub 2019 Apr 18.

Department of Psychiatry, Yale School of Medicine, 300 George St. #901, New Haven, CT 06511, USA.

Premorbid personality traits have been implicated as risk factors for the development of behavioral and psychological symptoms of dementia (BPSD), although there is a paucity of studies investigating this relationship. In this narrative review, a number of studies found that premorbid neuroticism has consistently been observed to have a significant association with the development of BPSD symptoms while premorbid conscientiousness, extraversion, openness and agreeableness may be protective factors against future BPSD symptoms. In conclusion, premorbid personality traits appear to affect the risk of BPSD symptoms among individuals with dementia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0044DOI Listing

'Likelihood to be diagnosed or misdiagnosed': application to meta-analytic data for cognitive screening instruments.

Neurodegener Dis Manag 2019 Apr 18. Epub 2019 Apr 18.

Cognitive Function Clinic, Walton Center for Neurology & Neurosurgery, Liverpool, UK.

To extend use of the recently described 'likelihood to be diagnosed or misdiagnosed' (LDM) metric for test accuracy studies through application to recent meta-analytic data of commonly used cognitive screening instruments. Raw data (true positives and negatives, false positives and negatives) were extracted from meta-analyses (minimum 5 studies or 1000 patients), from which LDM was calculated. LDM values were compared with those previously reported for single test accuracy studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0041DOI Listing

Usability of a daily mHealth application designed to address mobility, speech and dexterity in Parkinson's disease.

Neurodegener Dis Manag 2019 Apr 18. Epub 2019 Apr 18.

Program in Physical Therapy, Washington University School of Medicine, St Louis, MO, USA.

This study investigated the usability of a mobile health (mHealth) smartphone application to treat gait, speech and dexterity in people with Parkinson's disease. Participants either used an mHealth application (intervention) or maintained their normal routine (control) for 12 weeks and were evaluated at baseline and post-test time points for primary outcome measures of adherence, gait, speech and dexterity. mHealth application adherence was compared with percent change scores on gait, speech and dexterity measures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0036DOI Listing

Abdominal functional electrical stimulation for bowel management in multiple sclerosis.

Neurodegener Dis Manag 2019 Apr 18. Epub 2019 Apr 18.

Birmingham Community Healthcare NHS Foundation Trust, UK.

Functional constipation is common in multiple sclerosis (MS) and first line treatments are frequently ineffective. The current study explored the use of abdominal functional electrical stimulation (ABFES) for treating constipation in MS. Twenty people with MS and constipation (ROME IV criteria). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0043DOI Listing

Valbenazine in the treatment of tardive dyskinesia.

Neurodegener Dis Manag 2019 Feb 6. Epub 2019 Feb 6.

Rush University Medical Center, Section of Movement Disorders, Rush Parkinson's Disease & Movement Disorders Program, 1725 W Harrison St., Suite 755, Chicago, IL 60612, USA.

Tardive dyskinesia (TD) is a bothersome and - at times, disabling - movement disorder associated with exposure to dopamine receptor antagonist medications. On 11 April 2017, valbenazine became the first US FDA-approved medication indicated for the treatment of TD. Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor that decreases the abnormal movements of TD. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/nmt-2019-0001
Publisher Site
http://dx.doi.org/10.2217/nmt-2019-0001DOI Listing
February 2019
4 Reads

Deutetrabenazine in the treatment of tardive dyskinesia.

Neurodegener Dis Manag 2019 Jan 31. Epub 2019 Jan 31.

Parkinson's Disease Center & Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, 77030, USA.

Tardive dyskinesia is a common movement disorder in the population of patients taking dopamine receptor blocking agents, such as antipsychotics and certain antiemetics, which likely lead to D2-receptor upregulation and hypersensitization. Efficacious and well-tolerated treatments are now available to reduce symptoms. Deutetrabenazine, a reversible inhibitor of vesicular monoamine transporter 2, was US FDA-approved for treatment of tardive dyskinesia in 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0042DOI Listing
January 2019
8 Reads

Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.

Authors:
Francesco Patti

Neurodegener Dis Manag 2019 Apr 18;9(2s):3-7. Epub 2019 Jan 18.

Department 'GF Ingrassia', Section of Neurosciences, Multiple Sclerosis Center, University of Catania, Catania, Italy.

Postapproval studies have an essential role in demonstrating that an intervention is effective and well tolerated during use in daily clinical practice. Numerous large observational and registry studies of tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray have been conducted subsequent to its approval in Europe in 2011. Collectively, these studies provide valuable insight into various aspects of THC:CBD spray during real-world use in patients with multiple sclerosis spasticity, including its long-term effectiveness and tolerability. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/nmt-2018-0049
Publisher Site
http://dx.doi.org/10.2217/nmt-2018-0049DOI Listing
April 2019
7 Reads

Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.

Authors:
Jolana Marková

Neurodegener Dis Manag 2019 Apr 18;9(2s):9-13. Epub 2019 Jan 18.

Neurology Department, Charles University, 3rd Faculty of Medicine and Thomayer Hospital, Czechia.

Subsequent to EMA approval of tetrahydrocannabinol (THC): cannabidiol (CBD) oromucosal spray based on results of various studies, including an enriched-design clinical trial, two newer postapproval randomized trials have confirmed its efficacy and safety for treating resistant multiple sclerosis spasticity, while simultaneously addressing specific authorities' concerns. A double-blind, placebo-controlled, Phase IV trial, conducted as part of the EMA's risk management plan, found no effect of THC:CBD spray on cognition and mood after 50 weeks of treatment. In the Sativex as add-on therapy versus further optimized first-line ANTispastics (SAVANT)  study, add-on THC:CBD spray was significantly more effective than readjusting standard antispasticity therapy and provided new evidence of efficacy as requested by German authorities. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/nmt-2018-0050
Publisher Site
http://dx.doi.org/10.2217/nmt-2018-0050DOI Listing
April 2019
5 Reads

Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.

Authors:
Tjalf Ziemssen

Neurodegener Dis Manag 2019 Apr 18;9(2s):1-2. Epub 2019 Jan 18.

Center of Clinical Neuroscience, University Clinic Carl Gustav Carus Dresden, Dresden, Germany.

Proceedings of an Almirall-sponsored satellite symposium held at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Berlin, Germany, 10 October 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0048DOI Listing
April 2019
3 Reads

Introducing Volume 9 of Neurodegenerative Disease Management.

Authors:
Laura Dormer

Neurodegener Dis Manag 2019 Feb 14;9(1):1-4. Epub 2019 Jan 14.

Commissioning Editor - Neurodegenerative Disease Management Future Medicine Ltd, Unitec House, London, N3 1QB, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0051DOI Listing
February 2019

Person-centered risk assessment framework: assessing and managing risk in older adults living with dementia.

Neurodegener Dis Manag 2019 Feb 14;9(1):47-57. Epub 2019 Jan 14.

Center for Family Medicine Family Health Team, McMaster University, 10 B Victoria Street South, Kitchener, Ontario N2G 1C5, Canada.

Aim: This study pilot-tested the person-centered risk assessment framework (PCRAF), a framework for managing risk among persons living with dementia (PLWD) in primary care.

Methods: Healthcare providers (N = 7) piloting the PCRAF completed a survey, rating their satisfaction with the tool, and an interview to gather their perceptions of the PCRAF. PLWD and care partners (N = 12) completed a survey, rating their satisfaction with safety planning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0031DOI Listing
February 2019
1 Read

Deutetrabenazine in the treatment of Huntington's disease.

Neurodegener Dis Manag 2019 Feb 9;9(1):31-37. Epub 2019 Jan 9.

Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

Deutetrabenazine (DTBZ) is a US FDA-approved treatment for chorea in Huntington's disease. The substitution of deuterium for hydrogen at specific positions imparts a longer half-life on DTBZ, allowing for less-frequent daily dosing. As a reversible vesicular monoamine transporter Type 2 inhibitor, DTBZ depletes monoamines at presynaptic nerve terminals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0040DOI Listing
February 2019
10 Reads

Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis.

Neurodegener Dis Manag 2019 Feb 18;9(1):25-30. Epub 2018 Dec 18.

Ionis Pharmaceuticals, Carlsbad, CA, USA.

Hereditary  transthyretin amyloidosis (ATTR) is a fatal systemic disease that results from deposition of the misfolded protein transthyretin (TTR) in tissues. Common clinical manifestations of ATTR include peripheral neuropathy, cardiomyopathy, autonomic dysfunction, diarrhea and constipation. Historically there have not been effective therapies for this devastating disease. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/nmt-2018-0037
Publisher Site
http://dx.doi.org/10.2217/nmt-2018-0037DOI Listing
February 2019
2 Reads

Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry.

Neurodegener Dis Manag 2019 Feb 14;9(1):39-46. Epub 2018 Dec 14.

Department of Neuroscience, Padua University, Padua, Italy.

Aim: To evaluate long-term effects of levodopa-carbidopa intestinal gel on dyskinesia burden.

Patients & Methods: Posthoc analysis of the GLORIA registry assessed subgroups of advanced Parkinson's disease patients with <4 and ≥4 h/day of levodopa-induced dyskinesia at baseline.

Results & Conclusions: Mean dyskinesia duration significantly (p < 0. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/nmt-2018-0034
Publisher Site
http://dx.doi.org/10.2217/nmt-2018-0034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360350PMC
February 2019
9 Reads

Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.

Neurodegener Dis Manag 2019 Feb 27;9(1):5-23. Epub 2018 Nov 27.

Amyloidosis Research & Treatment Centre, Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy.

Hereditary transthyretin-mediated amyloidosis is a rapidly progressive, heterogeneous disease caused by the accumulation of misfolded transthyretin protein as amyloid fibrils at multiple sites, and is characterized by peripheral sensorimotor neuropathy, autonomic neuropathy and/or cardiomyopathy. Current treatment options have limited efficacy and often do not prevent disease progression. Patisiran is a novel RNA interference therapeutic that specifically reduces production of both wild-type and mutant transthyretin protein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0033DOI Listing
February 2019
5 Reads

Persons with dementia and care partners' perspectives on memory clinics in primary care.

Neurodegener Dis Manag 2018 12 19;8(6):385-397. Epub 2018 Nov 19.

Centre for Family Medicine Family Health Team, McMaster University, 10 B Victoria Street South, Kitchener, N2G 1C5 Ontario, Canada.

Aims: To understand persons with dementia (PWD) and care partners' experiences with the Primary Care Collaborative Memory Clinic (PCCMC) care model.

Methods: Interviews were conducted with a purposeful sample of PWD (n = 12) and care partners (N = 16) to identify their perspectives of care received in the clinic and suggestions for improvement.

Results: PWD and care partners were satisfied with care received within the PCCMC, had positive interactions with and perceived a strong sense of support from team members and felt listened to; the necessity of cognitive testing was recognized but disliked. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0024DOI Listing
December 2018
20 Reads

5-HT receptors and Parkinson's disease psychosis: a pharmacological discussion.

Authors:
Philippe Huot

Neurodegener Dis Manag 2018 12 19;8(6):363-365. Epub 2018 Nov 19.

Neurodegenerative Disease Group, Montreal Neurological Institute, Montreal, QC H3A 2B4, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0039DOI Listing
December 2018
2 Reads

Functional cognitive disorders: demographic and clinical features contribute to a positive diagnosis.

Neurodegener Dis Manag 2018 12 19;8(6):377-383. Epub 2018 Nov 19.

Cognitive Function Clinic, Walton Centre for Neurology & Neurosurgery, Liverpool, UK.

Aim: To examine features associated with functional cognitive disorders (FCDs) compared with neurological cognitive disorders (dementia, mild cognitive impairment, transient amnesias) in consecutive patients referred to a secondary care cognitive disorders clinic.

Methods: Patients diagnosed with either neurological cognitive disorder or FCD were compared by demographic (age, gender, handedness, referral source) and clinical features (family history of dementia, clinical signs, Likert screening measure of subjective memory complaint, mini-Addenbrooke's Cognitive Examination).

Results: Patients diagnosed with FCD were younger than those with neurological cognitive disorders, and more likely to attend alone, have a family history of dementia and be categorized as positive for subjective memory complaint. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/nmt-2018-0025
Publisher Site
http://dx.doi.org/10.2217/nmt-2018-0025DOI Listing
December 2018
21 Reads

The place of transcranial direct current stimulation in the management of multiple sclerosis-related symptoms.

Neurodegener Dis Manag 2018 12 19;8(6):411-422. Epub 2018 Nov 19.

Service de Physiologie, Explorations Fonctionnelles, Hôpital Henri-Mondor, AP-HP, 94010 Créteil, France.

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, characterized by chronic inflammation, demyelination, synaptopathy and neurodegeneration. Patients may exhibit sensory, motor, cognitive, emotional and behavioral symptoms throughout their disease process. Nowadays, the challenge is to find optimal treatment for MS symptoms, especially that available pharmacological interventions are faced by modest therapeutic outcomes and numerous side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0028DOI Listing
December 2018
4 Reads

Physician and patient treatment decision-making in relapsing-remitting multiple sclerosis in Europe and the USA.

Neurodegener Dis Manag 2018 12 19;8(6):371-376. Epub 2018 Nov 19.

Ipsos Healthcare, London.

Objective: To assess factors used in treatment decision-making for relapsing-remitting multiple sclerosis in both the 5EU (UK/Germany/France/Italy/Spain) and the USA.

Methods: Data were abstracted from the Ipsos Healthcare Global Multiple Sclerosis Therapy Monitor (data abstracted September-December, 2015-2017) a bi-annual online chart-review study of patients with multiple sclerosis.

Results: Treatment choices were primarily due to efficacy for relapses while convenience factors, other than oral administration, were uncommon. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0023DOI Listing
December 2018

The BETACONNECT™ system: MS therapy goes digital.

Neurodegener Dis Manag 2018 12 3;8(6):399-410. Epub 2018 Oct 3.

Bayer Vital GmbH, Leverkusen, Germany.

Adherence to long-term treatment in chronic diseases such as multiple sclerosis is challenging. Many disease-modifying drugs (DMDs) for MS need to be injected. Injection devices may improve satisfaction with the injection procedure and boost adherence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0030DOI Listing
December 2018
2 Reads

The role of optical coherence tomography and infrared oculography in assessing the visual pathway and CNS in multiple sclerosis.

Neurodegener Dis Manag 2018 10 18;8(5):323-335. Epub 2018 Sep 18.

Department of Neurology, Amsterdam Neuroscience, VU University Medical Centre, Amsterdam, The Netherlands.

In this review, a current overview is provided of how optical coherence tomography and infrared oculography can aid in assessing the visual system and CNS in multiple sclerosis (MS). Both afferent and efferent visual disorders are common in MS and visual complaints can have a tremendous impact on daily functioning. Optical coherence tomography and infrared oculography can detect and quantify visual disorders with high accuracy, but could also serve as quantitative markers for inflammation, neurodegeneration and network changes including cognitive decline in MS patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0011DOI Listing
October 2018
1 Read

Naturally occurring change in Multiple Sclerosis Walking Scale-12 scores over time in multiple sclerosis.

Neurodegener Dis Manag 2018 10 18;8(5):315-322. Epub 2018 Sep 18.

Department of Kinesiology & Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA 61801.

Aim: This study examined the trajectory and pattern of naturally occurring change in perceived walking impairment over a 30-month period in relapsing-remitting multiple sclerosis (RRMS).

Patients & Methods: Two hundred and sixty-nine persons with RRMS completed the 12-item Multiple Sclerosis Walking Scale (MSWS-12) every 6 months over a 30-month period. Data were analyzed using latent growth curve modeling and latent class growth curve modeling. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/nmt-2018-0016
Publisher Site
http://dx.doi.org/10.2217/nmt-2018-0016DOI Listing
October 2018
10 Reads

Assessing the benefit of treatment in chronic inflammatory demyelinating polyneuropathy: the challenges of clinical practice.

Neurodegener Dis Manag 2018 10 18;8(5):285-288. Epub 2018 Sep 18.

Aston Brain Centre, School of Life & Health Sciences, Aston University, Birmingham, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0027DOI Listing
October 2018
3 Reads

Speech disorders in Parkinson's disease: pathophysiology, medical management and surgical approaches.

Neurodegener Dis Manag 2018 10 18;8(5):337-348. Epub 2018 Sep 18.

Department of Otolaryngology, Loma Linda University School of Medicine, Loma Linda, CA, USA.

The prevalence of speech disorders among individuals with Parkinson's disease (PD) has been reported to be as high as 89%. Speech impairment in PD results from a combination of motor and nonmotor deficits. The production of speech depends upon the coordination of various motor activities: respiration, phonation, articulation, resonance and prosody. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0021DOI Listing
October 2018
2 Reads

Mini-Mental State Examination: diagnostic test accuracy study in primary care referrals.

Authors:
Andrew J Larner

Neurodegener Dis Manag 2018 10 18;8(5):301-305. Epub 2018 Sep 18.

Cognitive Function Clinic, Walton Centre for Neurology & Neurosurgery, Lower Lane, Fazakerley, Liverpool, UK.

Aim: To undertake a diagnostic test accuracy study of the Mini-Mental State Examination (MMSE) administered in primary care to patients who were subsequently referred to a cognitive disorders clinic in secondary care (n = 72).

Methods: MMSE scores from primary care were cross-classified with reference standard diagnoses made in secondary care, blind to MMSE score, in order to calculate standard measures of discrimination (including sensitivity and specificity, positive and negative predictive values).

Results: MMSE showed poor sensitivity (0. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/nmt-2018-0018
Publisher Site
http://dx.doi.org/10.2217/nmt-2018-0018DOI Listing
October 2018
6 Reads

Freezing of Gait Boot Camp: feasibility, safety and preliminary efficacy of a community-based group intervention.

Neurodegener Dis Manag 2018 10 18;8(5):307-314. Epub 2018 Sep 18.

Program in Physical Therapy, Washington University School of Medicine in St. Louis, St. Louis, MO 631082, USA.

Aim: In this pilot study, we evaluated the feasibility, safety and preliminary efficacy of a 6-week, community-based group intervention designed to reduce freezing of gait (FOG) for people with Parkinson's disease (PD).

Methods: Seven people with PD completed 'FOG Boot Camp' provided by the St. Louis Chapter of the American Parkinson Disease Association. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391635PMC
October 2018
2 Reads

Identifying a new subtype of multiple sclerosis.

Neurodegener Dis Manag 2018 12 14;8(6):367-369. Epub 2018 Sep 14.

Medicine Institute, Mellen Center for Treatment & Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.

Dr Bruce Trapp and Dr Daniel Ontaneda speak to Laura Dormer, Commissioning Editor: Bruce D Trapp, PhD, is a Chair of the Department of Neurosciences at the Lerner Research Institute, Cleveland Clinic (OH, USA) and Professor of Molecular Medicine at Case Western Reserve University (OH, USA). Dr Trapp received his PhD from Loyola University Stritch School of Medicine in Chicago (IL, USA). Dr Trapp's research investigates the cause of neurological disability in multiple sclerosis patients, cellular mechanism of brain repair in neurodegenerative diseases and the molecular biology of myelination in the central and peripheral nervous systems. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0032DOI Listing
December 2018
1 Read

A report from the 8th Kuopio Alzheimer Symposium.

Neurodegener Dis Manag 2018 10 16;8(5):289-299. Epub 2018 Aug 16.

Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.

The international Kuopio Alzheimer Symposium was organized by the University of Eastern Finland in Kuopio, Finland on June 6-8, 2018 for the 8th time. Approximately 300 researchers in the fields of neuroscience and neurology from 12 different countries around the world gathered to Kuopio to hear and discuss about the latest insights into the mechanisms and comorbidities and novel approaches for diagnosis, prediction, prevention and therapies of Alzheimer's disease and other neurodegenerative diseases. The 2-day international program on June 7-8 included a keynote session, five oral scientific sessions and a poster session. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0029DOI Listing
October 2018
2 Reads

Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia.

Neurodegener Dis Manag 2018 08 27;8(4):233-242. Epub 2018 Jul 27.

Bioelectron Technology Corporation, Mountain View, CA, 94043 USA.

Aim: To evaluate the safety and clinical effects of EPI-743 in Friedreich's ataxia patients. EPI-743 is a compound that targets oxidoreductase enzymes essential for redox control of metabolism.

Methods: We conducted a multicenter trial that evaluated EPI-743 during a 6-month placebo-controlled phase, followed by an 18-month open-label phase. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0013DOI Listing
August 2018
1 Read

Cardiovascular function is related to neuromuscular performance in Parkinson's disease.

Neurodegener Dis Manag 2018 08 25;8(4):243-255. Epub 2018 Jul 25.

Department of Kinesiology & Dance, New Mexico State University, Las Cruces, NM, 88003, USA.

Aim: The current study examined the relationship of handgrip, leg and arm neuromuscular performance with cardiovascular function in patients with Parkinson's disease (PD).

Materials & Methods: Blood pressure, vascular measures and handgrip, shoulder and leg neuromuscular performance were obtained in PD persons and healthy controls.

Results: The data reveal that muscular and cardiovascular functions are altered (p < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2017-0058DOI Listing
August 2018
3 Reads

Features on cerebral imaging suggesting mitochondrial disorder.

Authors:
Josef Finsterer

Neurodegener Dis Manag 2018 08 24;8(4):215-216. Epub 2018 Jul 24.

Krankenanstalt Rudolfstiftung, Messerli Institute, Veterinary University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0015DOI Listing
August 2018
3 Reads

Cannabinoids for the treatment of behavioral and psychological symptoms of dementia.

Neurodegener Dis Manag 2018 08 24;8(4):211-213. Epub 2018 Jul 24.

Diamond Healthcare, Richmond, VA, 23219, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0019DOI Listing
August 2018
2 Reads

5-HT agonists and dyskinesia in Parkinson's disease: a pharmacological perspective.

Authors:
Philippe Huot

Neurodegener Dis Manag 2018 08 24;8(4):207-209. Epub 2018 Jul 24.

Neurodegenerative Disease Group, Montreal Neurological Institute, Montreal, QC, H3A 2B4, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0017DOI Listing
August 2018
1 Read

Psychometric properties of apathy scales in Parkinson's disease: a systematic review.

Neurodegener Dis Manag 2018 08 24;8(4):267-282. Epub 2018 Jul 24.

Department of Psychiatry, Sunnybrook Research Institute, Toronto, Ontario, Canada.

Apathy is among the most prevalent neuropsychiatric symptom experienced in Parkinson's disease (PD) and can be assessed with a variety of scales. To identify which scale is most suitable for apathy assessment in PD, the psychometric properties of each scale and its sensitivity to change were analyzed. The methodological quality of the studies ranged from adequate to excellent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0010DOI Listing
August 2018
7 Reads

Dementia in 'super-aged' Japan: challenges and solutions.

Neurodegener Dis Manag 2018 08 24;8(4):257-266. Epub 2018 Jul 24.

Department of Medical Bioengineering, Graduate School of Natural Science & Technology, Okayama University, Okayama, Japan.

Japan, as a 'super-aged' society, is at the forefront of the socioeconomic change resulting from the unprecedented demographic shift of aging societies, and is an exemplar for other countries. Within neurodegenerative disorders, a deeper understanding of the issues faced by aging societies, and their ramifications on the mental well being and cognitive health of older adults, is important. Japan's pioneering approaches in assistive technology and 'gerontotechnology' have the potential to enhance the field of dementia in terms of assessment, diagnosis and care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0007DOI Listing
August 2018
4 Reads

Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.

Neurodegener Dis Manag 2018 10 5;8(5):349-360. Epub 2018 Jul 5.

Unit of Functional Neurosurgery at UCL Institute of Neurology and the National Hospital for Neurology & Neurosurgery, London, UK.

In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation catechol-O-methyl transferase inhibitor, and safinamide, a monoamine oxidase B inhibitor. This clinical consensus outlines the practical considerations relating to motor fluctuations and managing wearing-off in patients with PD, and provides a clinical insight to adjunctive treatment options, including opicapone and safinamide. Practice-based opinion was provided from a multidisciplinary steering Group of eight UK-based movement disorder and PD specialists, including neurologists, geriatricians and a nurse specialist, from England, Scotland and Wales. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0020DOI Listing
October 2018
6 Reads

Reflections of the use of locating technologies with persons with dementia: proceedings of a key stakeholder forum.

Neurodegener Dis Manag 2018 06;8(3):195-205

Department of Occupational Therapy, University of Alberta, 1-45 Corbett Hall, Edmonton, AB T6G 2G4, Canada.

Aim: To describe the proceedings and outcomes of a Locating Technology and Dementia Forum that brought together 109 representatives of researchers, product manufacturers, policy makers, Alzheimer Societies, clinicians, first responders, persons with dementia and care partners.

Methods: Information gathered from this event was used to create strategic direction for advancing the development and use of locating technologies among persons with dementia.

Results: Key recommendations from this forum include the need to: fund and conduct research pertaining to usability and effectiveness of technologies; increase awareness about the risk of missing person events; develop a guideline of strategies to manage critical wandering; and engage users in technology development and evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0002DOI Listing
June 2018
1 Read

Myasthenia gravis: the unmet needs of a paradigmatic autoimmune disease.

Authors:
Pedro J Modrego

Neurodegener Dis Manag 2018 06;8(3):137-139

Department of Neurology, Hospital Miguel Servet, Isabel la católica 1-3. Zaragoza -50009, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0014DOI Listing
June 2018
4 Reads

Phase III SUNBEAM and RADIANCE PART B trials for Ozanimod in relapsing multiple sclerosis demonstrate superiority versus interferon-β-1a (Avonex) in reducing annualized relapse rates and MRI brain lesions.

Authors:
Volker Koscielny

Neurodegener Dis Manag 2018 06;8(3):141-142

Celgene, Boudry, Switzerland.

Biography: Volker Koscielny, MD, is the Vice President, Global Medical Affairs, for Inflammation and Immunology at Celgene. Volker trained as a doctor in his native Germany and worked for several pharmaceutical companies prior to joining Celgene in January 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0012DOI Listing
June 2018
1 Read

Increases in fatigue do not change spasticity scores in persons with multiple sclerosis.

Neurodegener Dis Manag 2018 06;8(3):143-150

Department of Physical Therapy, Hunter College, The City University of New York, New York, NY 10010, USA.

Aim: Fatigue is a common finding in multiple sclerosis (MS) which may result in worsening of gait, function and other MS symptoms, like spasticity. Although the worsening of spasticity with fatigue has been reported by persons with MS, the effect of fatigue on spasticity has not been measured.

Purpose: The purpose of this study was to compare lower extremity Modified Ashworth Scale (MAS) scores of persons with mild-to-moderate MS symptoms before and after fatigued and unfatigued conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2017-0049DOI Listing
June 2018
25 Reads

Role of epigenetics in Alzheimer's disease pathogenesis.

Neurodegener Dis Manag 2018 06 11;8(3):181-193. Epub 2018 Jun 11.

Department of Translational Research & New Technologies in Medicine & Surgery, Section of Medical Genetics, University of Pisa, Via Roma 55, 56126 Pisa, Italy.

Advances in molecular biology technologies have allowed uncovering the role of epigenetic regulation in several complex diseases, such as cancer and neurodegenerative disorders. Although the role of epigenetic mechanisms in Alzheimer's disease is still little understood, recent findings clearly show that such mechanisms are dysregulated during disease progression, already in its early stages. However, it is not clear if the observed epigenetic changes represent a cause or a consequence of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0004DOI Listing
June 2018
19 Reads

Dopamine, BDNF and motor function postbilateral anodal transcranial direct current stimulation in Parkinson's disease.

Neurodegener Dis Manag 2018 06 11;8(3):171-179. Epub 2018 Jun 11.

Department of Rehabilitation Sciences, Jordan University of Science & Technology, Irbid 22110, Jordan.

Aim: To examine BDNF, dopamine, and motor function changes after bilateral anodal transcranial direct current stimulation (tDCS) in patients with Parkinson's disease.

Methods: 20 patients undertook ten sessions of bilateral anodal tDCS stimulation applied simultaneously over FC1/FC2, targeting left and right prefrontal and motor areas. Dopamine and BDNF serum levels, and Movement Disorders Society - Unified Parkinson's Disease Rating Scale part three (MDS-UPDRS-III) total score and disability sub-scores were examined pre/post-tDCS stimulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2017-0048DOI Listing
June 2018
6 Reads

Repository corticotropin injection in multiple sclerosis: an update.

Neurodegener Dis Manag 2018 08 5;8(4):217-225. Epub 2018 Jun 5.

Kansas City Multiple Sclerosis Center College Park Neurology, 10600 Mastin, Overland Park, KS 66208, USA.

Relapse management is a crucial component of multiple sclerosis care. Acute relapses are defined as new neurological symptoms or worsening of existing symptoms persisting for >24 h that are not attributable to heat, overexertion, or infection. The most commonly used treatment for multiple sclerosis relapse is a 3-5-day course of corticosteroids, primarily intravenous methylprednisolone with or without oral steroid taper. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0008DOI Listing
August 2018
21 Reads

Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.

Neurodegener Dis Manag 2018 06 31;8(3):151-159. Epub 2018 May 31.

Unidad de Neurología, Hospital General de Elda, Elda (Alicante), Spain.

Aim: To examine evolution in activities of daily living (ADL) in patients with multiple sclerosis spasticity during long-term use of tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray.

Methods: Functional impairment was assessed retrospectively (prior to start of treatment) and at the present moment using a 16-item ADL survey; results were compared. A control group without add-on THC:CBD oromucosal spray was included to investigate possible recall bias. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2017-0055DOI Listing
June 2018
5 Reads

Treatment and comorbidities of multiple sclerosis in an employed population in Japan: analysis of health claims data.

Neurodegener Dis Manag 2018 04 25;8(2):97-103. Epub 2018 Apr 25.

Department of Neurology, Brain Research Institute, Niigata University, 1-757 Asahimachidori, Chuo-ku, Niigata 951-8585, Japan.

Aim: Use real-world data to investigate the treatment, comorbidities and prevalence of multiple sclerosis (MS) in an employed Japanese population.

Methods: Data from the Japanese Medical Data Center health insurance claims database were analyzed (January 2005-November 2014). Patients with claims associated with an MS diagnosis were identified (n = 494) and comorbidities and prescribed treatments were investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2017-0047DOI Listing
April 2018
4 Reads

Toward adaptive deep brain stimulation in Parkinson's disease: a review.

Neurodegener Dis Manag 2018 04 25;8(2):115-136. Epub 2018 Apr 25.

Department of Electronic & Electrical Engineering, University College London, Torrington Place, London WC1E 7JE, UK.

Clinical deep brain stimulation (DBS) is now regarded as the therapeutic intervention of choice at the advanced stages of Parkinson's disease. However, some major challenges of DBS are stimulation induced side effects and limited pacemaker battery life. Side effects and shortening of pacemaker battery life are mainly as a result of continuous stimulation and poor stimulation focus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2017-0050DOI Listing
April 2018
5 Reads

Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.

Neurodegener Dis Manag 2018 04 23;8(2):105-113. Epub 2018 Apr 23.

Multiple Sclerosis Center, II Division of Neurology, Department of Clinical & Experimental Medicine, Second University of Naples, Naples, Italy.

Aim: Complaints about Δ-tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray (Sativex; GW Pharma Ltd, Salisbury, UK) in the management of multiple sclerosis spasticity include unpleasant taste and oral mucosal anomalies. This pilot study assessed the use of sugar-free chewing gum and/or a refrigerated bottle of THC:CBD oromucosal spray to mitigate these effects.

Materials & Methods: Patients with multiple sclerosis spasticity (n = 52) at six sites in Italy who were receiving THC:CBD oromucosal spray and had associated oral mucosal effects were randomized into Group A (chewing gum; n = 15); Group B (cold bottle; n = 20); and Group C (cold bottle + chewing gum; n = 17). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2017-0056DOI Listing
April 2018
6 Reads

Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease.

Neurodegener Dis Manag 2018 06 10;8(3):161-170. Epub 2018 Apr 10.

Department of Neurology, Medical University of Innsbruck, Innsbruck, A-6060, Austria.

Aim: To determine if age and Parkinson's disease duration at therapy initiation influence the efficacy of levodopa-carbidopa intestinal gel (LCIG) on quality of life and activities of daily living.

Patients & Methods: This post hoc analysis assessed subgroups of patients stratified by baseline age, disease duration, hours/day of 'off' time and levodopa equivalent dose. Patients' data were collected from the GLORIA study, a 24-month observational registry evaluating long-term effectiveness of LCIG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2017-0046DOI Listing
June 2018
11 Reads

The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.

Neurodegener Dis Manag 2018 04 22;8(2):73-80. Epub 2018 Mar 22.

Department of Neurology, University of Kansas Medical Center, KS, USA.

Levodopa is the most efficacious treatment for Parkinson's disease (PD). Long-term treatment with levodopa is limited due to dyskinesia. Dyskinesia in PD can be socially and functionally disabling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0001DOI Listing
April 2018
7 Reads